Difei Yang

Despite a second-quarter earnings loss, Audentes Therapeutics, Inc. (NASDAQ: BOLD)’s existing catalysts are reason enough for a bullish stance, according to Mizuho.  The Analyst Mihuzo analyst Difei Yang upgraded Audentes Therapeutics from Neutral to Buy and raised the price target...

A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN) moving towards the end of the year. The Analyst Mizuho’s Difei Yang upgraded shares of FibroGen from...

Concert Pharmaceuticals Inc (NASDAQ: CNCE) announced Friday the Patent Trial and Appeal Board decided not to grant the company a Post Grant Review petition in the patent '335 dispute with Incyte Corporation (NASDAQ: INCY). The Analyst Mizuho Securities' Difei Yang decided to downgrade the...

Aegis Capital’s Difei Yang believes Zeltiq Aesthetics Inc (NASDAQ: ZLTQ) is well positioned to take “the lion’s share” of the developing body contouring space globally and sees large market opportunity for the company’s “standard setting” product,...

Brean Capital assumed coverage of Axsome Therapeutics Inc (NASDAQ: AXSM) with a Buy rating and $20 target price, implying a potential upside of 154 percent. The company's leading product candidate is AXS-02, a non-opioid therapeutic in development for chronic pain. AXS-02 is being studied...

Brean Capital assumed coverage of SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and target price of $16, implying a potential upside of 313 percent. Scynexis is focusing on the unmet needs surrounding resistant fungal infections. Its lead product candidate, SCY-078, is triterpene glucan...

Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is set to lead in the migraine market, at least according to Brean Capital, which has assumed coverage on the stock with a Buy rating and price target of $45. The company's lead product candidate, ALD403, a novel monoclonal antibody delivered...

Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR) with Buy rating and $23 price target on strong growth in royalties from recent and future new launches. "In our view, Nektar's products from recent/future launches that are likely to generate the most upside are: Movantik,...

Brean Capital assumes coverage of Akebia Therapeutics Inc (NASDAQ: AKBA) with a Buy rating, with a lowered target price of $18, citing potential success of its anemia drug. The company's lead product candidate, AKB-6548 or vadadustat is a small molecule oral drug being studied to treat anemia...